Literature DB >> 7690782

Genotype dependence of hepatitis C virus antibodies detectable by the first-generation enzyme-linked immunosorbent assay with C100-3 protein.

R Nagayama1, F Tsuda, H Okamoto, Y Wang, T Mitsui, T Tanaka, Y Miyakawa, M Mayumi.   

Abstract

Hepatitis C virus (HCV) samples in 155 sera, from patients with chronic non-A, non-B liver disease and blood donors, were grouped into four genotypes (I, II, III, and IV) by amplification of core-gene sequences by polymerase chain reaction with type-specific primers. HCV genotypes were compared with various HCV-associated antibodies detectable by the first-generation ELISA (ELISA-1) with C100-3 protein and a second-generation immunoblot assay with four recombinant HCV proteins. Antibodies to C100-3 protein and those to its subsequence (5-1-1) were detected in 13 (93%) and 12 (86%), respectively, of 14 sera with genotype I HCV; 56 (79%) and 58 (82%) of 71 sera with genotype II; 13 (34%) and 6 (16%) of 38 sera with genotype III; and 11 (34%) and 4 (13%) of 32 sera with genotype IV. Amino acid sequences of C100-3 of genotype I HCV are conserved by approximately 90% in genotype II, but only by approximately 75% in genotypes III and IV. The sensitivity of ELISA-1, therefore, would be influenced by heterogeneity in C100-3 sequences of different genotypes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690782      PMCID: PMC288299          DOI: 10.1172/JCI116731

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection.

Authors:  H Okamoto; F Tsuda; A Machida; E Munekata; Y Akahane; Y Sugai; K Mashiko; T Mitsui; T Tanaka; Y Miyakawa
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

2.  New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus.

Authors:  H J Alter
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

3.  A new type of hepatitis C virus in patients in Thailand.

Authors:  S Mori; N Kato; A Yagyu; T Tanaka; Y Ikeda; B Petchclai; P Chiewsilp; T Kurimura; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1992-02-28       Impact factor: 3.575

4.  Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions.

Authors:  H Okamoto; S Okada; Y Sugiyama; K Kurai; H Iizuka; A Machida; Y Miyakawa; M Mayumi
Journal:  J Gen Virol       Date:  1991-11       Impact factor: 3.891

5.  Immunity in hepatitis C infection.

Authors:  A M Prince; B Brotman; T Huima; D Pascual; M Jaffery; G Inchauspé
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

6.  Sensitivity of serological assays to identify blood donors with hepatitis C viraemia.

Authors:  M Sugitani; G Inchauspé; M Shindo; A M Prince
Journal:  Lancet       Date:  1992-04-25       Impact factor: 79.321

7.  Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay.

Authors:  J Bukh; R H Purcell; R H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes.

Authors:  H Okamoto; K Kurai; S Okada; K Yamamoto; H Lizuka; T Tanaka; S Fukuda; F Tsuda; S Mishiro
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

9.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants.

Authors:  S W Chan; F McOmish; E C Holmes; B Dow; J F Peutherer; E Follett; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

10.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

Authors:  H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  7 in total

1.  Analysis of hepatitis C virus isolates by serotyping and genotyping.

Authors:  L J van Doorn; B Kleter; I Pike; W Quint
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

2.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia, multiple myeloma and chronic lymphocytic leukemia.

Authors:  S Gharagozloo; J Khoshnoodi; F Shokri
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups.

Authors:  H Tokita; H Okamoto; F Tsuda; P Song; S Nakata; T Chosa; H Iizuka; S Mishiro; Y Miyakawa; M Mayumi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

4.  Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam.

Authors:  P Song; D D Duc; B Hien; S Nakata; T Chosa; J Watanabe; F Tsuda; K Murata; H Okamoto
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

5.  HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile.

Authors:  S Shev; A Widell; U Foberg; A Frydén; S Hermodsson; G Lindh; A Lindholm; S Månsson; O Weiland; G Norkrans
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 6.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

7.  Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay.

Authors:  J H Kao; M Y Lai; Y T Hwang; P M Yang; P J Chen; J C Sheu; T H Wang; H C Hsu; D S Chen
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.